Pilr-β2 Inhibitors
Pilr-β2 inhibitors belong to a class of chemical compounds that specifically interact with the paired immunoglobulin-like type 2 receptor beta (PILRβ2), which is a protein encoded by a gene in various species, including humans. These inhibitors are designed to modulate the activity of this receptor through their specific binding properties. PILRβ2 itself is a member of the paired receptor family, which often consists of both inhibitory and activating counterparts that play roles in the modulation of immune responses. The structure of these inhibitors is carefully tailored to ensure a high affinity and selectivity for the target receptor, which involves a complex interaction between the small molecule and the specific domains of the protein. Such interactions are typically characterized by non-covalent bonds, including hydrogen bonds, van der Waals forces, and sometimes ionic interactions, depending on the chemical structure of the inhibitor and the nature of the active site on the receptor.
The design of Pilr-β2 inhibitors is informed by detailed knowledge of the receptor's molecular structure, often obtained through techniques like X-ray crystallography or NMR spectroscopy. These structural insights allow chemists to craft molecules that can achieve a precise fit within the receptor's binding domain, akin to a key fitting into a lock. The molecular architecture of Pilr-β2 inhibitors may include a variety of chemical moieties, such as aromatic rings, heteroatoms, and linkers, that contribute to the affinity and specificity of the interaction. The physicochemical properties of these inhibitors, such as solubility, stability, and molecular weight, are also critical considerations in their design, as these characteristics affect the ability of the compound to interact with its target receptor. The precise mechanism by which Pilr-β2 inhibitors exert their activity involves the stabilization of certain receptor conformations or the blocking of the binding site, preventing the natural ligand from associating with the receptor, thereby modulating the receptor's function at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor blocker that can alter cytokine production. Since Pilr-β2 is implicated in immune cell signaling, the alteration of cytokine environments by Losartan could impinge on Pilr-β2-mediated pathways, leading to reduced activity of Pilr-β2 in the immune response. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that impairs the MAPK/ERK pathway. Since the MAPK pathway can regulate the expression of various immune receptors, inhibiting this pathway can indirectly decrease the expression or activity of Pilr-β2 by altering downstream immune signaling that Pilr-β2 might be a part of. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in inflammatory responses and cytokine production. Inhibiting this pathway can reduce the functional activity of Pilr-β2 by diminishing the inflammatory signals that may enhance Pilr-β2 signaling in immune cells. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that blocks the MAPK/ERK pathway. It indirectly lessens Pilr-β2 activity by potentially reducing the expression of immune receptors or modulators that are part of the same immune response pathways as Pilr-β2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor which can modulate the immune response by affecting the AP-1 transcription factor. Given Pilr-β2's role in immune signaling, inhibition of JNK might indirectly lead to decreased Pilr-β2 activity by altering the immune response context in which Pilr-β2 operates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. PI3K is involved in multiple signaling pathways, including those that regulate immune responses. By inhibiting PI3K, Wortmannin could indirectly affect Pilr-β2 activity by altering downstream signaling events that involve Pilr-β2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that undermines signaling pathways crucial for cell survival and function in the immune system. Its action may lead to an indirect decrease in Pilr-β2 activity by affecting signaling cascades that Pilr-β2 is linked to. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF 1120 is a multi-kinase inhibitor that can disrupt angiogenesis and various signaling pathways. By influencing the signaling environment, BIBF 1120 could indirectly decrease the activity of Pilr-β2 by altering the expression or function of molecules in pathways that Pilr-β2 is associated with. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $99.00 | 6 | |
D4476 is a casein kinase 1 (CK1) inhibitor. CK1 is involved in Wnt and other signaling pathways. By inhibiting CK1, D4476 could indirectly affect Pilr-β2 activity by altering signaling pathways that regulate immune cell function and receptor expression, including those that may involve Pilr-β2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Since Src kinases are involved in immune cell receptor signaling, Dasatinib could indirectly decrease Pilr-β2 activity by modulating the signaling landscape of immune cells where Pilr-β2 functions. | ||||||